| Size | Price | |
|---|---|---|
| 250mg | ||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Xylose has been shown to enter the aqueous humor of rats via systemic circulation, thereby reaching the lens. Absorption/ Absorbed via the gastrointestinal tract…5 g dose…absorbed more quickly and completely than the 25 g dose…at least 60%…absorbed in the proximal small intestine…independent of the presence of bile or pancreatic juice… Peak Plasma Concentration/1 to 2 hours…decreases to 0 after 5 hours (human, oral 5 g or 25 g). Plasma Half-Life…approximately 1 hour (intravenous administration)…approximately 60%…metabolized to carbon dioxide and water, D-threitol, and…unidentified metabolites…excreted in the urine…approximately 25% of the 25 g/dose and approximately 35% of the 5 g/dose are excreted unchanged in the urine within 5 hours (human, oral). Urinary Excretion/Primarily via glomerular filtration…a small amount of tubular reabsorption may occur (human, oral). For more complete data on the absorption, distribution, and excretion of (D)-xylose (8 types), please visit the HSDB record page. Metabolism/Metabolites ……Rat liver microsomal catalysis……xylose transfer to bilirubin, from……UDP-xylose…… Approximately 60% of absorbed xylose is metabolized to carbon dioxide and water, D-threitol, and other unidentified metabolites/human, oral/. After intraperitoneal injection of (14)C-labeled D-xylose into guinea pigs, 10.8 radioactive carbon dioxide was recovered from exhaled carbon dioxide within 4 hours and 41.3 radioactive (14) carbon was recovered from urine within 5 hours. Approximately 60% of the radioactivity in urine was D-xylose. (14)C-labeled D-xylose can be oxidized to labeled carbon dioxide in the kidneys and liver of intact animals, both in vivo and in vitro. The oxidation of D-xylose in guinea pigs may involve its initial conversion to D-xylose followed by decarboxylation. In vitro, the kidneys and liver can oxidize D-xylose to carbon dioxide. Liver extracts can catalyze its conversion to D-xylonic acid with pyridine nucleotides as a cofactor. This enzyme activity differs from that of hepatic glucose dehydrogenase. |
|---|---|
| Toxicity/Toxicokinetics |
Interactions
D-xylose mitigated the inhibitory effects of puromycin and cyclohexylimide on the incorporation of chondroitin sulfate into embryonic chicken cartilage. Addition of guar gum during oral administration of D-xylose in volunteers slowed gastrointestinal absorption. Total D-xylose absorption and plasma half-life were unaffected. Concomitant administration of indomethacin, neomycin, phenformin, colchicine, or high doses of aminosalicylic acid inhibited intestinal absorption of D-xylose, thereby reducing glucose excretion… Aspirin reduced urinary excretion of D-xylose, possibly by altering renal function. Non-human Toxicity Values Oral LD50 in mice: 23 g/kg Intravenous LD50 in mice: 11,300 mg/kg |
| Additional Infomation |
Aldehyde-D-xylose is a type of D-xylose. It is a metabolite in both humans and Saccharomyces cerevisiae. DL-xylose has been reported in Elliottia paniculata, Tecoma stans, and other organisms with relevant data. Aldehyde-D-xylose is a metabolite found or produced in Saccharomyces cerevisiae. See also: D-xylose (note moved here).
Therapeutic Uses Xylose Blood Concentration Assay… used to determine whether abnormally low urinary xylose excretion is due to malabsorption or renal insufficiency. Blood Xylose Level / Assay / 2 hours after administration of a 25g dose. / Differentiation / Steatorrhea due to pancreatic insufficiency versus steatorrhea due to malabsorption / 5g dissolved in 150ml water or 25g dissolved in 250ml water, followed by oral administration of 250ml water. Urine is collected and xylose content is determined over the next 5 hours. Assess intestinal absorption…Diagnose malabsorption caused by intestinal mucosal disease/Dissolve 5g in 150ml of water, or 25g in 250ml of water, then orally administer 250ml of water. Collect urine and determine xylose levels within the next 5 hours. Diagnose malabsorption caused by… /Assess/ the degree of malabsorption or treatment response/5g dissolved in 250ml of water orally. Fluid supplementation is permitted. Collect urine at 2 and 3 consecutive hours. Determine xylose levels/. For incontinent infants, young children, or elderly patients…Intestinal absorption can be assessed using xylose blood concentrations/500mg/kg body weight (or a maximum dose of 25g), orally in a 5-10% aqueous solution. Xylose levels are determined by collecting blood samples at 30 minutes, 1 hour, and 2 hours after xylose administration. Drug Warnings Urinary xylose excretion is generally lower in patients over 60 years of age…Xylose testing should only be used in pregnant women or women who may become pregnant when the potential benefit outweighs the possible risks. Situations that may lead to false positive test results include: vomiting, gastric retention, thyroid dysfunction, and severe diarrhea after taking the test dose. Patients with thyrotoxicosis have increased urinary xylose excretion. Close attention to technical details is required when using xylose tests… Patients with impaired renal function, dehydration, insufficient circulating blood volume, edema, or massive ascites may have lower than normal urinary D-xylose excretion, leading to false positive test results. |
| Molecular Formula |
C5H10O5
|
|---|---|
| Molecular Weight |
150.1299
|
| Exact Mass |
150.053
|
| CAS # |
25990-60-7
|
| Related CAS # |
25702-75-4
|
| PubChem CID |
644160
|
| Appearance |
White to off-white solid powder
|
| Density |
1.757g/cm3
|
| Boiling Point |
333.2ºC at 760mmHg
|
| Melting Point |
133-136ºC
|
| Flash Point |
155.3ºC
|
| LogP |
-2.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C([C@H]([C@@H]([C@H](C=O)O)O)O)O
|
| InChi Key |
PYMYPHUHKUWMLA-VPENINKCSA-N
|
| InChi Code |
InChI=1S/C5H10O5/c6-1-3(8)5(10)4(9)2-7/h1,3-5,7-10H,2H2/t3-,4+,5+/m0/s1
|
| Chemical Name |
(2R,3S,4R)-2,3,4,5-tetrahydroxypentanal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~125 mg/mL (~832.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (333.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6609 mL | 33.3045 mL | 66.6089 mL | |
| 5 mM | 1.3322 mL | 6.6609 mL | 13.3218 mL | |
| 10 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02314455 | Terminated | Other: D-xylose | Eosinophilic Esophagitis | Mayo Clinic | September 2014 | Not Applicable |
| NCT02654301 | Completed | Dietary Supplement: Test 1 Dietary Supplement: Test 2 |
Postprandial Hyperglycemia | Yonsei University | June 2014 | Not Applicable |
| NCT01957098 | Completed | Dietary Supplement: Active comparator: 4% D-xylose |
Insulin Resistance | University of Copenhagen | October 2006 | Not Applicable |
| NCT03243994 | Completed | Diagnostic Test: Absorption test with D-xylose and zink |
Chronic Obstructive Pulmonary Disease Cor Pulmonale |
Jens Rikardt Andersen | February 1, 2016 | Not Applicable |